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Introduction
Actinium-225 labeled antibodies and small molecules targeting prostate specific antigen (PSMA) are currently being evaluated in clinical trials, and reports have already shown promising therapeutic results in prostate cancer (PCa) patients resistant to androgen receptor (AR)-inhibiting drugs [1] [2] [3] . Unfortunately, toxicities generated by off-target accumulation in radio-sensitive tissues, such as salivary glands and kidneys, is of growing concern 4,5 . In addition, PSMA expression decreases with increasing AR activity and has been shown to be unevenly expressed in metastases [6] [7] [8] [9] . We have developed an antibody-based platform that targets human kallikrein 2 (hK2), an AR regulated prostate enzyme, specifically expressed at abundant levels in prostate derived tissues. In enzalutamide resistant disease, in which the glucocorticoid receptor (GR) drives the AR-pathway, PSMA expression is lost while hK2 is still highly expressed 10 . Our group has previously reported on the targeting specificity, efficacy and biological response of radiolabeled hu11B6 as an immunotheranostic vehicle. Preclinical evaluations have been carried out in multiple immunodeficient and immunocompetent, rodent disease models as well as in non-human primates 3, [11] [12] [13] [14] . In addition, studies of the uptake mechanism have revealed that hu11B6 is internalized by hK2 expressing cells via a mechanism driven by the neonatal Fc receptor (FcRn); while uncomplexed hu11B6 is released from the cell by recycling endosomes after binding to FcRn, the hu11B6-hK2 complex is routed to lysosomes for processing 12 . The proximity of the internalized radionuclide-labeled hu11B6 to the nucleus results in efficient cell kill, which is further accelerated by inherent AR and hK2 upregulation related to DNA-repair 3 .
In the current report we investigated alternative strategies to further improve the therapeutic efficacy of hu11B6. In the field of nuclear medicine, the fragment crystallizable (Fc) is commonly ablated to increase blood clearance. However, these modifications also obliterate possibilities to exploit radiolabeled monoclonal antibodies (mAbs) to orchestrate Fc-receptor activated cytotoxic effects. IgG3 activates complement and Fc-gamma-receptor (FcγR)-mediated functions more efficiently than other subclasses. We therefore investigated if changing the subclass of hu11B6 from IgG1 to IgG3 could improve therapeutic efficacy. However, wild-type IgG3 has low FcRn binding capacity due to an arginine at amino acid (aa) position 435 (R435), abrogating cellular internalization 15 . To overcome this, we constructed a H435 (i.e., histidine at aa 435) containing hu11B6 IgG3 allotype, generating hu11B6-IgG3 R435H . As another optimization step, we evaluated therapeutic efficacy of a single high activity vs. two lower activity fractions. Lastly, we examined the genetic profile of PCa tumors resistant to [ 225 Ac]hu11B6-IgG1 therapy. In summary, while IgG3 has shown increased immunotherapeutic efficacy compared to IgG1 [16] [17] [18] , no advantage was shown when applied as a radiolabeled compound targeting hK2. Although susceptible to retreatment, tumors relapsing after [ 225 Ac]hu11B6-IgG1 showed upregulation of several oncogenes related to aggressive disease.
Results
Radiochemistry. The radiochemical yield for the [ 225 Ac]DOTA-hu11B6 product using a one-step labeling method was 60.2%  29.3% (n=5). The product was 98.5%  2.0% (n=5) radiochemically pure and the specific activity was 0.068 Ci/g ± 0.032 Ci/g (2. 516 GBq/g ± 1.184 GBq/g; n=5). The radiochemical yields for the four hu11B6 combinations prepared using a two-step radiolabeling method were as follows: [ 225 Ac]hu11B6-IgG1 (native IgG1), 3 post-injection (Figure 1a) . LNCaP-AR tumor models led to similar findings; [ 225 Ac]hu11B6-IgG3 R435H showed significantly (p=0.1653 at 4h, p=0.0003 at 72h, p=0.0132 at 240h p.i.) higher tumor uptake compared to [ 225 Ac]hu11B6-IgG3, 8.45±4.28 and 0.86±0.79 %IA/g (SD), respectively, at 10d post-injection (Figure 1b) (C) and 7.86 (D) weeks after administration of 300 nCi (11 kBq), respectively (A vs. B, p<0.0001; C vs. D, p=0.0020; A vs. C, p=0.0536) (Figure 2a ). Assessment of volumetric effects showed that mice treated with [ 225 Ac]hu11B6-IgG3 R435H had reduced tumor growth kinetics compared to [ 225 Ac]hu11B6-IgG3 (Figure 2b) . However, [ 225 Ac]hu11B6-IgG1 outperformed [ 225 Ac]hu11B6-IgG3 R435H (Figure 2c) ; at the conclusion of the study, half of the animals treated with the specific and internalizing [ 225 Ac]hu11B6-IgG1 drug were alive, while only one animal was alive in the group that received [ 225 Ac]hu11B6-IgG3 R435H . tumors and uptake at 400 hrs p.i. was significantly (p=0.0020) higher than in PC3 tumors at the same time-point (Figure 3a) . In GEMM, the highest specific uptake of [ 225 Ac]hu11B6 was found in prostate lobes (Figure 3b ). In summary, biodistribution profile of 1-step labeled [ 225 Ac]hu11B6 closely resembled our previously published results based on the 2-step labeled [ 225 Ac]hu11B6 compound 3 . Therefore, the one-step labelling protocol was used for all further studies.
Therapeutic efficacy of fractionated vs. single activity [ 225 Ac]hu11B6-IgG1 alpha RIT. Bilaterally inoculated LNCaP-AR s.c. xenografts were used in both treatment studies. Therapeutic effects were monitored by tumor size (caliper measurements) and assessment of PSA in blood. In the fractionated treatment experiment, animals (n=10) were randomized to receive 300 nCi (11 kBq) [ 225 Ac]hu11B6 (n=5) or no treatment (n=5). Previously treated mice were given a second injected activity (300 nCi; 11 kBq) 20 weeks after the first treatment. Tumors were either fully eradicated or substantially reduced after each treatment round; 5 of 8 (63%) and 2 of 5 (40%) tumors relapsed after the first activity and second activity administration, respectively (Figure 4a; Supplemental   Figure 2a ). In the single high-activity treatment experiment, xenografts (n=10) were randomized to receive a single activity 600 nCi (22 kBq) of [ 225 Ac]hu11B6 (n=5) or no treatment (n=5). All tumors were eradicated (tumors not palpable and PSA not detectable); during the study period, only 1 of 6 (17%) tumors relapsed (Figure 4b; Supplemental Figure 2b ). Mice that had lost weight (≥20% weight loss) at the end of the high-activity study were euthanized and send for autopsy evaluation. These reports concluded age-related macroscopic and histopathologic but no treatment-related pathological changes. Comparing fractionated vs. single activity treatment median survival was not reached (80% of the cohort had survived at the conclusion of the study) following 600 nCi (22 kBq), whereas 2x 300 nCi (2x 11 kBq) resulted in a median survival of 40.3 weeks after the first treatment (p=0.3186 vs. high-activity) (Figure 4c, d) . Table 1 ). Figure 5 gives an overview of all DEGs and Tabels 2 and 3 summarize the top 10 upregulated and down-regulated genes.
Discussion
Recently approved drugs that target AR signaling such as abiraterone and enzalutamide have rapidly become standard therapies for advanced-stage prostate cancer 19, 20 . Initial responses are usually observed, but in an absolute majority of these patients, reactivation of the AR-pathway inevitably occurs within 6 to 12 months. An alternative treatment option is to target tumors using radiolabeled antibodies or small molecules, a technology that is highly dependent on the specificity of the vehicle and target expression in non-malignant tissues. We have developed an antibodybased platform that targets hK2, an enzyme that is prostate tissue-specific and under direct regulation of AR, the central driver of prostate adenocarcinoma. Our lead antibody, hu11B6, has been thoroughly evaluated for tumor detection and monitoring of disease activity by positron emission tomography and single photon emission computed tomography 12, 14 . We have reported that hu11B6 can be applied for RIT applications 3, 11, 13 . In the current report we aimed to evaluate previously untested and innovative methods that could further increase efficacy. First, we evaluated if therapeutic efficacy could be improved by altering the Fc-subclass. Second, we assessed the impact of dosing strategies. Finally, to determine radio-biological mechanisms that could appropriate combination therapies or elucidate potential drug resistance, we genetically profiled tumors that relapsed after prolonged treatment.
Induction of DNA damage, tumor cell death and modulation of tumor microenvironment are the main effects of ionizing radiation to reduce tumor masses, but also to effectuate the immune system 21 . Therefore, we investigated if the therapeutic efficacy of [ 225 Ac]hu11B6 could be improved by exploiting the complement-, and FcγR binding capacities of the mAb. We constructed an Fc-substituted hu11B6; from IgG1-Fc to IgG3-Fc. Compared to IgG1, wild-type IgG3 has an arginine instead of a histidine at the aa position 435. Although both residues are positively charged, arginine does not deprotonate at neutral pH, resulting in a less pH dependent binding to FcRn. To rescue FcRn-mediated internalization, we introduced a histidine at the aa position 435 22 , generating a hu11B6-IgG3-R435H. Indeed, this optimization is critical as almost no effect was noted with [ 225 Ac]hu11B6-IgG3, while [ 225 Ac]hu11B6-IgG3-R435H produced a relatively potent therapeutic outcome. Biodistribution in immunodeficient tumor models and immunocompetent GEMM indicated that [ 225 Ac]hu11B6-IgG3-R435H is less stable than its IgG1 counterpart; significantly higher uptake in immunoglobulin-degrading organs were noted. This is probably due to the long hinge region of IgG3, which is more prone to proteolytic degradation 23 .
Based on our results, [ 225 Ac]hu11B6-IgG3-R435H did not show any therapeutic advantage over [ 225 Ac]hu11B6-IgG1. However, the lack of increased efficacy could be due to critical differences between mouse and human FcγR networks. For example, mouse natural killer (NK) cells express mFcγRIII, while human NK cells express hFcγRIIIA. hFcγRIIIA is a key mediator of antibody therapy in humans, while mFcγRIII only modestly contributes to mAb efficacy 24, 25 .
Therefore, experiments based on GEMM expressing human FcγRs would be needed in order to fully elucidate whether RIT efficacy can be enhanced by using Fc-engineered mAbs. Our approach of exploiting Fc-engineered mAbs for RIT is novel. In the field of nuclear medicine, the Fc region has been viewed as redundant and various Fc-edited antibody-like platforms have been invented 26 . Omitting the Fc-region decreases the half-life of the antibody by escaping FcRn-interaction and permitting renal clearance. However, Fc contains motifs for activation of both effector immune cells and the classical pathway of the complement (C1q). One of the most important breakthroughs in the field of immunology during the last two decades is the discovery and characterization of the Fc-portion interaction with FcγR which orchestrates mAb dependent cellular cytotoxicity through cytotoxic effects via agonistic and antagonistic binding 27 . The specific FcγR engaged by a given Fc domain is dictated by Fc structure which is determined by the IgG subclass. An example of the multifaceted therapeutic activity are checkpoint-inhibitor mAbs (e.g., anti-CTLA4) that mediate antitumor activity by altering the composition and functional activity of leukocytes within the tumor microenvironment. However, the therapeutic action is also an effect of the capacity of the mAb to activate FcγR expressing macrophages within the tumor microenvironment 28 . Radiation has been shown to induce immune-modulatory effects. Both preclinical and clinical studies have shown that radiation enhances the activity of immune checkpoint blockers and thereby promotes systemic antitumor responses 29 . The capacity of radiation therapy to promote immune-modulatory effects is now the subject of intense scientific and clinical investigation. Based on these observations, a radiolabeled full sized mAb might have the unique capacity to target its antigen while inducing immune-modulatory effects and activate Fc receptor mediated cytotoxicity.
Although a single high activity may deliver optimal absorbed dose to kill a larger fraction of tumor cells, fractionated therapy could offer the advantage of lower myelotoxicity and prolonged tumor response. In accordance to previous studies based on [ 177 Lu]hu11B6, results showed that the therapeutic effect of [ 225 Ac]hu11B6 is absorbed dose dependent; fewer tumors relapsed in mice treated with a higher activity 13, 30 . All of our previous evaluations of [ 225 Ac]hu11B6-RIT studies were based on evaluation of a single activity. In the current study, Figure 2 ) and were successfully treated by a second activity. Also, more than a year after treatment no imminent organ toxicities were noted at necropsy.
In addition to deregulated AR regulated genes, further analysis of the transcriptome of relapsing tumors revealed an intriguing profile. Among the most strongly upregulated genes were ETV1, MMP7, TMEFF2, SCHLAP1 and NTS. ETV1 predisposes prostate cells for cooperation with other oncogenic events such as PTEN loss, leading to more aggressive disease in murine models and human patients 33 . ETV1 expression is associated with enrichment of steroid hormone biosynthesis pathway and androgen and estrogen metabolism by binding to HSD17B7, a gene shared by steroid biosynthesis and steroid hormone biosynthesis pathways. In accordance with this, we found HSD17B7 to be significantly up-regulated in [ 225 Ac]hu11B6 resistant tumors (p=2.27*10 -7 ). MMP7 is a tumor biomarker associated with increased risk for metastases and poor survival, including prostate cancer 34, 35 . TMEFF2 has been reported as an AR-regulated protein 36 that can function both as an oncogene and as a tumor suppressor by affecting Akt and ERG activation 37 . While the full length intracellular TMEFF2 acts as a tumor suppressor [38] [39] [40] , the shed ectodomain promotes growth 39 . Successful immuno-targeting of TMEFF2 expressing PCa tumors has been reported and applied for both positron emission tomography (PET)-imaging and antibody-drug conjugates [41] [42] [43] . Therefore, in vivo imaging and co-treatment with TMEFF2targeted compounds could be a potential option to monitor resistance and increase therapeutic efficacy of molecularly targeted alpha-therapy. Similarly, NTS-based radioligands have been developed for theranostic use 44, 45 . NTS/ NTS receptor signaling has, amongst others, been associated with prostate cancer exhibiting neuroendocrine features such as down-regulation or loss of AR and PSA 46, 47 . Thus, NTS-based imaging and therapy may be an option to monitor transition to to this very aggressive phenotype and to complement [ 225 Ac]hu11B6 RIT. Lastly, SCHLAP1
has been shown to be a reliable biomarker strongly associated with a shorter time to metastatic progression, biochemical relapse, and prostate-cancer-specific mortality [48] [49] [50] .
The field of molecularly targeted alpha-therapy is currently undergoing clinical translation, including a planned [ 225 Ac]hu11B6 trial. In the current study, we built on previous preclinical studies of hK2-targeted RIT by investigating novel methods to enhance therapeutic efficacy and explore prospective treatment strategies. To the best of our knowledge, this is the first study showing that FcRn-optimized IgG3 subforms can be applied to RIT. Although further studies are needed to replicate our findings, we also discovered a constellation of putative biomarkers associated with resistance to alpha-RIT.
Methods
Reagents and cell culture. Reagents were purchased from Sigma-Aldrich unless otherwise noted.
Cell growth media were obtained from the Media Preparation Core Facility at Memorial Sloan Kettering Cancer Center (MSKCC, New York, NY). LNCaP-AR (LNCaP cell line with overexpression of wild-type AR and luciferase under the control of the ARR2-Pb promoter) was a kind gift from the laboratory of Dr. Charles Sawyers, which previously developed and reported the cell line 51 . PC3 was purchased from American Type Culture Collection (ATCC). All cell lines were cultured according to the developer's instructions and regularly tested for mycoplasma.
Antibodies. Hu11B6-IgG1, hu11B6-IgG3 R435H , hu11B6-IgG3, and hu11B6-IgG1 H435A used for an Actinium-225 labeling protocol using two steps were developed by DiaProst AB (Lund, Sweden) and produced by Innovagen AB (Lund, Sweden). Pre DOTA-conjugated hu11B6-IgG1 applicable for a one step labeling protocol was developed by Diaprost AB (Lund, Sweden) and produced by Fuji-Biosyth (London, England).
Radiochemistry. Carrier-free solid 225 Actiniumnitrate (5.80 × 10 4 Ci/g; 214.6 x 10 4 GBq/g), Oak
Ridge National Laboratory, Oak Ridge, TN) was assayed at secular equilibrium with a CRC-15R radioisotope calibrator (Capintec, Inc., Florham Park, NJ). All reagents were American Chemical Society reagent grade or better. Radiolabeling procedures were performed using sterile metal-free and pyrogen-free plasticware (Corning, Inc.). The radiometal chelate 1,4,7,10tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was conjugated to the hu11B6 antibody to yield DOTA-hu11B6 and radiolabeled in one-step as previously described 52 . Briefly, 0.005 mL of 225 Ac-nitrate dissolved in 0.2 M HCl (Fisher Scientific) (0.1 mCi; 3.7 MBq) was mixed with 1.0 to 1.5 mg of DOTA-hu11B6-IgG1 and buffered with 0.1 mL of 2 M tetramethylammonium acetate and 0.01 mL of 150 g/L of L-ascorbic acid to pH 5.5. The clear and colorless reaction mixture was heated at 37C for 75-110 minutes. The reaction was quenched with 0.02 mL of 50 mM diethylenetriaminepentaacetic acid and purified via size exclusion chromatography using a Bio-Rad 10DG column stationary phase with a 1% human serum albumin (HSA, Swiss Red Cross, Bern, Switzerland) and 0.9% sodium chloride (normal saline solution, Abbott Laboratories, North Chicago, IL) mobile phase. Four combinations of native and mutated, IgG1 and IgG3 isoforms of hu11B6 (i.e., native IgG1, H435A mutant IgG1, wild-type IgG3 and R435H mutant IgG3 were 225 Ac-radiolabeled using a previously described two-step method to prepare alpha emitting nanogenerators 53 . Radiochemical purity was determined by instant thin-layer chromatography using silica gel-impregnated paper (Gelman Science Inc., Ann Arbor, MI) using two mobile phases. Mobile phase I was 10 mM ethylenediaminetetraacetic acid; mobile phase II was 9% sodium chloride/10 mM sodium hydroxide. Activity was measured at secular equilibrium using a Packard gamma counter to count the signal in the 370-510 keV energy window. The binding kinetics of native [ 225 Ac]DOTA-hu11B6, DOTA-hu11B6, and hu11B6 against recombinant hK2 analyte was measured by surface plasmon resonance (SPR) using a Biacore 2000 (GE Healthcare, Marlborough, MA) as previously described 3 . Antibodies and constructs were captured on a Protein A sensor chip (GE Healthcare) 54 Therapy studies. In the initial studies, the therapeutic efficacies of 300 nCi (11 kBq) [ 225 Ac] on 5 μg hu11B6-IgG1, hu11B6-IgG1 H435A , hu11B6-IgG3, and hu11B6IgG3 R435H , labeled using a two-step protocol, were compared in s.c. LNCaP-AR tumors and GEMM. In a subsequent study, two different treatment regimens of labeled hu11B6-IgG1 labeled using a one-step protocol were evaluated; single activity treatment (600 nCi; 22 kBq) was compared to fractionated administration (300 + 300 nCi; 11 + 11 kBq) [ 225 Ac]hu11B6-IgG1 in s.c. LNCaP-AR tumors (5 mice/treatment group and 5 untreated mice/treatment group). Length (l) and width (w) of the tumors were measured by caliper and tumor volume was calculated using the modified formula for a rotated ellipsoid (V = ½ w 2 l) 55 was calculated. Weight loss of 20% or a tumor diameter exceeding 15 mm was set as an endpoint. Survival percentages over time were calculated to study therapy effectiveness in both studies.
Measurement of kallikreins. Free (fPSA) and total (tPSA) PSA were determined with the duallabel DELFIA immunofluorometric assay (Prostatus™ PSA Free/Total PSA from Perkin-Elmer Life Sciences Turku, Finland). This assay determines free and complexed PSA in an equimolar fashion, and the cross-reaction for PSA-alpha 1-antichymotrypsin (PSA-ACT) in the fPSA assay is below 0.2% 56 . The lower limit of detection for tPSA is 0.10 ng/ml (coefficient of variation of 5.0% at 2.32 ng/mL) and for fPSA 0.04 ng/mL (coefficient of variation of 5.9% at 0.25 ng/mL). hK2 was measured using an in-house research assay protocol 57 ; the detection limit of the assay is 0.005 ng/mL with assay imprecision values (mean coefficients of variation) ranging from 5.7% to 11% for high and low hK2 controls, respectively. 3 ). Hierarchical clustering of samples using the Manhattan method for distance calculation further demonstrated a clear divide between the two cohorts. To visualize the magnitude of effect and to highlight the groups of genes that were similar to each other based on their expression, a heatmap was plotted based on the log2 raw read counts (Supplemental Figure 4) .
Differential expression analysis of RNA-sequencing expression profiles was performed using Bioconductor's edgeR 58 package in R. edgeR implements statistical methods based on negative binomial distributions, namely empirical Bayes methods, that permit the estimation of gene-specific biological variation, even for experiments with minimal levels of biological replication. Raw read counts are provided as input where edgeR introduces possible bias sources into the statistical model to perform an integrated normalization followed by differential expression analysis. P-values and fold change in log 2 were calculated for each gene. P-values were adjusted for False Discovery Rate (FDR) using the Benjamini-Hochberg method.
Differentially expressed genes were then selected based on the following criteria: Adjusted p-value 
